These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Jallad RS; Musolino NR; Salgado LR; Bronstein MD Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910 [TBL] [Abstract][Full Text] [Related]
8. [Lowered ghrelin levels in acromegaly—normalization after treatment]. Kozakowski J; Rabijewski M; Zgliczyński W Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203 [TBL] [Abstract][Full Text] [Related]
9. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615 [TBL] [Abstract][Full Text] [Related]
10. Glycemic profile in patients with acromegaly treated with somatostatin analogue. Valea A; Carsote M; Ghervan C; Georgescu C J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517 [TBL] [Abstract][Full Text] [Related]
11. Outcome of pregnancies in a large cohort of women with acromegaly. Jallad RS; Shimon I; Fraenkel M; Medvedovsky V; Akirov A; Duarte FH; Bronstein MD Clin Endocrinol (Oxf); 2018 Jun; 88(6):896-907. PubMed ID: 29574986 [TBL] [Abstract][Full Text] [Related]
12. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408 [TBL] [Abstract][Full Text] [Related]
13. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390 [TBL] [Abstract][Full Text] [Related]
14. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Lorcy Y; Dejager S; Chanson P; Pituitary; 2000 Nov; 3(3):193-7. PubMed ID: 11383486 [TBL] [Abstract][Full Text] [Related]
15. Hormonal diagnosis of GH hypersecretory states. Grottoli S; Gasco V; Ragazzoni F; Ghigo E J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657 [TBL] [Abstract][Full Text] [Related]
16. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma]. Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144 [TBL] [Abstract][Full Text] [Related]